monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in The Lancet Infectious Diseases by researchers at the University of Maryland School of Medicine (UMSOM).
As evidence mounts supporting the use of monoclonal antibody treatment to reduce hospitalizations and deaths from COVID-19, UPMC and University of Pittsburgh School of Medicine physician-scientists are sharing the health system’s experience administering the life-saving medication.
UVA Health is offering monoclonal antibody drugs for appropriate patients with COVID-19 who are at highest risk for developing severe symptoms and requiring hospitalization.
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. The method – as well as a trio of successful animal studies on an antibody called “Ab1” – are described today in the Proceedings of the National Academy of Sciences. Ab1 is on track for human clinical trials by early next year.
COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not receive the antibody, according to a new study published in the The New England Journal of Medicine.
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.